- Home
- PRAX vs SMBK Comparison
PRAX vs SMBK Comparison
Compare PRAX & SMBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- SMBK
- Stock Information
- Founded
- PRAX 2015
- SMBK N/A
- Country
- PRAX United States
- SMBK United States
- Employees
- PRAX N/A
- SMBK N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- SMBK Major Banks
- Sector
- PRAX Health Care
- SMBK Finance
- Exchange
- PRAX Nasdaq
- SMBK Nasdaq
- Market Cap
- PRAX 599.7M
- SMBK 521.4M
- IPO Year
- PRAX 2020
- SMBK N/A
- Fundamental
- Price
- PRAX $38.55
- SMBK $31.70
- Analyst Decision
- PRAX Strong Buy
- SMBK Buy
- Analyst Count
- PRAX 10
- SMBK 5
- Target Price
- PRAX $116.50
- SMBK $34.40
- AVG Volume (30 Days)
- PRAX 320.6K
- SMBK 48.5K
- Earning Date
- PRAX 05-02-2025
- SMBK 07-21-2025
- Dividend Yield
- PRAX N/A
- SMBK 1.01%
- EPS Growth
- PRAX N/A
- SMBK 44.84
- EPS
- PRAX N/A
- SMBK 2.26
- Revenue
- PRAX $8,122,000.00
- SMBK $171,664,000.00
- Revenue This Year
- PRAX N/A
- SMBK $20.95
- Revenue Next Year
- PRAX N/A
- SMBK $9.48
- P/E Ratio
- PRAX N/A
- SMBK $14.06
- Revenue Growth
- PRAX 270.02
- SMBK 16.34
- 52 Week Low
- PRAX $26.70
- SMBK $21.40
- 52 Week High
- PRAX $91.83
- SMBK $37.72
- Technical
- Relative Strength Index (RSI)
- PRAX 53.72
- SMBK 54.92
- Support Level
- PRAX $35.21
- SMBK $30.68
- Resistance Level
- PRAX $38.90
- SMBK $32.27
- Average True Range (ATR)
- PRAX 2.09
- SMBK 0.61
- MACD
- PRAX 0.07
- SMBK -0.04
- Stochastic Oscillator
- PRAX 69.58
- SMBK 51.26
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About SMBK SmartFinancial Inc.
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.